Icahn scores a fortune on two big biotech plays

Carl Icahn may be the last person you'd want to see knocking on your biotech's front door, but investors who went along on his joyride at Biogen Idec and Genzyme have profited handsomely. Boston Globe columnist Steve Syre did the math and concluded that Icahn earned $614 million on his investment in Biogen and $237 million more on Genzyme. Altogether, that's a gain of $851 million. Says Syre: Executives don't like his rough tactics, but no one can argue about the results. Column

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.